PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
402.37%
G&A change of 402.37% while TRAW maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses change of 100.00% while TRAW maintains costs. Bruce Berkowitz would investigate efficiency.
547.73%
Operating expenses change of 547.73% while TRAW maintains costs. Bruce Berkowitz would investigate control.
547.73%
Total costs change of 547.73% while TRAW maintains costs. Bruce Berkowitz would investigate control.
3.95%
Interest expense change of 3.95% while TRAW maintains costs. Bruce Berkowitz would investigate control.
-96.03%
D&A reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
-2633.53%
EBITDA decline while TRAW shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-468.26%
Operating income decline while TRAW shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
6409.86%
Other expenses change of 6409.86% while TRAW maintains costs. Bruce Berkowitz would investigate control.
-429.59%
Pre-tax income decline while TRAW shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-75.15%
Tax expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
-263.73%
Net income decline while TRAW shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-197.18%
EPS decline while TRAW shows 0.00% growth. Joel Greenblatt would examine position.
-197.18%
Diluted EPS decline while TRAW shows 0.00% growth. Joel Greenblatt would examine position.
22.83%
Share count change of 22.83% while TRAW is stable. Bruce Berkowitz would verify approach.
22.83%
Diluted share change of 22.83% while TRAW is stable. Bruce Berkowitz would verify approach.